1 Department of Palliative, Rehabilitation, and Integrative Medicine, University of Texas , M.D. Anderson Cancer Center, Houston, Texas.
2 Department of Biostatistics, University of Texas , M.D. Anderson Cancer Center, Houston, Texas.
J Palliat Med. 2018 Oct;21(10):1408-1413. doi: 10.1089/jpm.2017.0670. Epub 2018 Jun 12.
Palliative care physicians often assist with pain management in children with cancer, but little is known about how they use long-acting opioids for chronic pain with these patients.
To determine the practices, attitudes, and beliefs of palliative care physicians toward the use of long-acting opioids in children with advanced cancer.
An electronic survey was sent to all members of The American Academy of Pediatrics (AAP) Section of Hospice and Palliative Medicine (SOHPM) and those identified as physicians who provide palliative care to children on the AAP SOHPM LISTSERV.
The response rate to the survey was 62% (116/188). A majority (66% [77/116]) of physicians are board certified in both pediatrics and hospice and palliative medicine. This represents 28% of all board-certified pediatric palliative care physicians. Most palliative care physicians report comfort in using long-acting opioids in children (84-94%), with the exception of long-acting hydromorphone (37%). Physicians perceived methadone as least costly (3%) but associated it with a higher perceived family resistance (51%). As compared with pediatric palliative care fellowship-trained physicians, nonpediatric fellowship-trained physicians perceived titration of oxycodone ER and morphine ER to be easier (p = 0.06, p = 0.07) and less likely to agree that the main reason for starting methadone is that the existing formulations of other long-acting opioids are unsuitable for children (p = 0.05).
Most physicians who provide palliative care to children are comfortable using opioids but there is significant variation in the level of comfort with different opioids. This information will be helpful in developing targeted education for palliative care providers.
姑息治疗医师通常在癌症患儿的疼痛管理中提供帮助,但对于他们在这些患者中如何使用长效阿片类药物治疗慢性疼痛知之甚少。
确定姑息治疗医师在使用长效阿片类药物治疗晚期癌症儿童方面的实践、态度和信念。
向美国儿科学会(AAP)姑息治疗和舒缓医学分会(SOHPM)的所有成员以及在 AAP SOHPM LISTSERV 上被确定为为儿童提供姑息治疗的医生发送了一份电子调查。
对该调查的回复率为 62%(116/188)。大多数医生(66%[77/116])在儿科学和姑息治疗与舒缓医学两个领域均获得委员会认证。这代表了所有获得委员会认证的儿科姑息治疗医师的 28%。大多数姑息治疗医师报告在使用儿童长效阿片类药物时感到舒适(84-94%),但不包括长效氢吗啡酮(37%)。医生认为美沙酮的成本最低(3%),但认为它的家庭阻力最高(51%)。与儿科姑息治疗 fellowship培训的医师相比,非儿科 fellowship培训的医师认为奥施康定 ER 和吗啡 ER 的滴定更容易(p=0.06,p=0.07),并且不太可能同意开始使用美沙酮的主要原因是其他长效阿片类药物的现有制剂不适合儿童(p=0.05)。
大多数为儿童提供姑息治疗的医生在使用阿片类药物方面感到舒适,但对不同阿片类药物的舒适度存在显著差异。这些信息将有助于为姑息治疗提供者提供有针对性的教育。